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Abstract
Background: Accurate antenna placement is essential for effective microwave ablation (MWA) of
lesions. Laparoscopic targeting is made particularly challenging in liver tumours by the needle's trajectory
as it passes through the abdominal wall into the liver. Previous optical three-dimensional guidance
systems employing infrared technology have been limited by interference with the line of sight during
procedures.
Objective: The aim of this study was to evaluate a newly developed magnetic guidance system for
laparoscopic MWA of liver tumours in a pilot study.
Methods: Thirteen patients undergoing laparoscopic MWA of liver tumours gave consent to their
participation in the study and were enrolled. Lesion targeting was performed using the InnerOptic AIM™
3-D guidance system to track the real-time position and orientation of the antenna and ultrasound probe.
Results: A total of 45 ablations were performed on 34 lesions. The median number of lesions per patient
was two. The mean ± standard deviation lesion diameter was 18.0 ± 9.2 mm and the mean time to target
acquisition was 3.5 min. The first-attempt success rate was 93%. There were no intraoperative or
immediate postoperative complications. Over an average follow-up of 7.8 months, one patient was noted
to have had an incomplete ablation, seven suffered regional recurrences, and five patients remained
disease-free.
Conclusions: The AIM™ guidance system is an effective adjunct for laparoscopic ablation. It facilitates
a high degree of accuracy and a good first-attempt success rate, and avoids the line of site interference
associated with infrared systems.
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Introduction
Treatment for liver cancers is often multimodal and can include
systemic chemotherapy, chemoembolization, external beam and
radioembolization, resection and/or ablation. For some cancers,
such as early-stage hepatocellular carcinoma (HCC), ablation is
reported to be just as effective as resection in terms of overall
survival.1,2 Liver tumour ablations are performed percutaneously
or surgically and require imaging that allows for the real-time
localization of the tumour in order to ensure the accurate guid-
ance and placement of the ablation device. Intraoperative imaging
of the liver with ultrasound (US) is an essential component in the
successful surgical ablation of hepatic tumours.3–5
Intraoperative US has been demonstrated to be more sensitive
than preoperative imaging modalities for detecting small (<1 cm)
tumours.6–9 However, a major limitation of US remains the pres-
entation of three-dimensional space (3-D) as two-dimensional
(2-D) tissue planes. This is particularly true when US is used to
target tumours for which the ablation needle and the lesion must
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be tracked simultaneously to facilitate the accurate intersection of
the needle into the tumour in order for complete ablation to be
achieved. Two-dimensional US requires a high degree of skill and
experience to allow accurate placement of an ablation device in
3-D space. The ability of experienced surgeons to hit a target in a
single pass using US guidance varies and is reported to be as low
as 59%.10
The present group has previously reported the use of 3-D guid-
ance systems in the performance of open hepatic tumour abla-
tions.11 The original device employed infrared (IR) tracking to
simultaneously track the positions of an US probe and a micro-
wave antenna in space. Virtual representations of these devices,
along with the US image, were displayed on a stereoscopic 3-D
monitor viewed by the operating surgeons. In a series of in vitro
studies, this system resulted in marked increases in first pass tar-
geting for novices and experienced surgeons, and was then trialled
successfully in human open liver tumour ablations.11 However, the
drawbacks of this system include the bulk of the IR tracking
reflectors and the reliance on a direct, uninterrupted line of sight
between the IR transmitter and the instruments. It was predicted
that the flex of the US probe and ablation antenna would make
targeting errors unacceptably high because the IR reflectors must
be mounted on the handle of the instruments and the system
must compute the position of the tip assuming that the instru-
ments are completely rigid.
A second-generation system was therefore created using an
electromagnetic tracking system in which sensors were embedded
in the tips of the US and microwave ablation (MWA) antenna
(Fig. 1a and b) (AIM™ Guidance System; InnerOptic Technology,
Inc., Hillsborough, NC, USA) and detection performed by placing
the target over a magnetic field. This removed line-of-sight limi-
tations associated with the IR system and avoided the adding of
Figure 1 (a) A laparoscopic ultrasound probe with attached field detector. A sterile rubber sheath is placed over the probe in this design. (b)
Microwave antenna with embedded sensor. (c) A magnetic field generator pad is placed beneath the patient on the operating table. Sensor
coils, attached to instruments, induce electrical currents as they move through the magnetic field. These inducted currents are recorded and
instrument position in three-dimensional space is calculated
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bulk to instruments. Furthermore, it allowed the position sensors
to be placed near the tips of the antenna and US probe, greatly
increasing accuracy and enabling the use of flexible articulating
US probes. Using in vitro and in vivo models, the present authors
demonstrated that the magnetic tracking system provided better
accuracy than IR tracking.10
The aim of this study was to evaluate the use of the InnerOptic
AIM™ guidance system in laparoscopic MWA of liver tumours in
a prospective human study.
Materials and methods
Institutional assurances
Approval for a human pilot study utilizing the AIM™ system for
laparoscopic MWA of liver tumours was obtained from the Caro-
linas Medical Center Institutional Review Board. All patients
would otherwise have been treated with traditional US and MWA.
Informed consent was obtained from all patients.
Review of guidance system
The basic electromagnetic guidance system has been reported by
the present group.10 The system (Aurora Measurement System;
Northern Digital, Inc., Waterloo, ON, Canada) records the 3-D
position and orientation of the ablation needle and laparoscopic
US transducer using a magnetic field generator pad placed under-
neath the patient (Fig. 1c). Small directional field detector coils
(0.3 mm in diameter, 13.0 mm in length) are installed on the
instruments themselves (Fig. 1a and b). Voltages are then induced
in the sensors when placed in the magnetic field; this information
is transmitted to the controller and allows for the calculation of
the real-time position of the instruments in space (Fig. 1c). As
electromagnetic energy is readily transmitted through human
tissues, the position of the device can be easily transmitted,
thereby overcoming the line-of-sight issues that arose using pre-
viously tested IR systems.
Once the controller calculates the position of the devices in the
field, graphical representations of the instruments (avatars) are
presented on a stereoscopic display. With the aid of 3-D glasses, the
operator can thus appreciate the real-time angles and positions of
the instruments in three dimensions (Figs 2 and 3). The 2-D US
image is simultaneously presented within this 3-D environment as
a projection from the tip of the US transducer avatar and in the
correct orientation to the US array. In effect, this presents the US
image and the instrument locations simultaneously on the screen.
In addition to co-localizing the ablation needle and antenna
with the US image, the system also projects the vector of the
ablation needle beyond its physical dimensions. This allows the
surgeon to project the intersection of the needle, as if it were to be
advanced from its existing position, with the US image and thus to
determine the angle of the needle prior to penetrating the skin.
The system also predicts the point of needle intersection within
Figure 1 Continued
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the US plane and projects this point artificially onto the US image
as a small purple box. Finally, once the needle has been success-
fully localized to the target lesion, an image of a spherical ‘cage’
can be superimposed to indicate the ablation zones predicted for
different power and time settings. The spherical cage is a red–
orange wire frame that is used to predict the volume of tissue to be
ablated. The cage size is set by the operating surgeon based on the
size of the tumour on preoperative imaging [three-phase com-
puted tomography (CT) scan]. It represents the size of ablation
the surgeon thinks is necessary to destroy the tumour completely.
Thus, the surgeon can be assured that all tissue designated for
destruction will be ablated and that no tissue or structures not
intended for ablation (such as blood vessels) are within the field
(Fig. 3).
Study design
The consent of 13 patients undergoing laparoscopic MWA of
hepatic tumours was acquired prior to their enrolment in this
pilot study. Targeting was performed using an InnerOptic AIM™
guidance system coupled with a ProFocus 2202 laparoscopic US
scanner and transducer (B-K Medical, Inc., Peabody, MA, USA).
Ablations were performed using a 1.8-mm cooled shaft antenna
with a 2.45-GHz generator (Accu2i; Microsulis Medical Ltd,
Denmead, UK). The primary endpoints of this Phase I trial were
30-day morbidity or mortality, local ablation success at the first
postoperative imaging scan, first-time pass rate, time to lesion
acquisition and time to disease progression with regional metas-
tases. Lesion acquisition was graded on a 5-point scale (1 = very
difficult, 5 = very easy).
Assessing ablation success
The completeness of ablation is quantified by two methods. The
first is during the ablation time, when colour Doppler imaging is
used to monitor ablation activity because there is a direct corre-
lation between the 2-D Doppler images and the actual
thermocoagulation zone in the liver tissue.12 The second method
refers to the use of a postoperative triphasic CT scan performed at
4–6 weeks post-procedure to determine the completeness of abla-
tion using the mRECIST criteria (modified response evaluation
criteria in solid tumours).
Statistics
GraphPad Prism Version 5.0 (GraphPad Software, Inc., La Jolla,
CA, USA) was used to complete all statistical analyses.
Results
A total of 45 ablations were performed on 34 lesions in 13
patients. The mean ± standard deviation (SD) patient age was 59.4
± 11.1 years (range: 43–85 years). Four of the 13 patients were
female (Table 1). The median number of lesions per patient was
two (range: one to five lesions). The median lesion size was 17 mm
(range: 5–40 mm).
The success rate of first-attempt passes with image guidance
was 93%; three lesions required two attempts each. The mean ±
SD time to lesion acquisition was 3.5 ± 2.6 min (range: 1–10 min).
Ease of lesion acquisition was assessed subjectively using a 5-point
scale. Of the 45 ablations, 27 were graded at 5 (very easy), four
were graded at 4 (easy), four were graded at 3 (moderate), none
were graded at 2 (difficult), and only one was graded at 1 (very
difficult). Nine ablations were performed without guidance as
they referred to surface lesions. The mean ± SD operative time was
91.9 ± 37.4 min (range: 46–177 min) and the mean ± SD hospital
length of stay was 2.8 ± 1.5 days.
The mean ± SD length of follow-up was 7.8 ± 4.2 months
(range: 0–16 months). One patient was lost from follow-up after
discharge and thus postoperative imaging for 12 of the 13 patients
was available (Fig. 4). An incomplete ablation was identified in
one patient on the first postoperative scan. In a 30-mm, solitary
HCC, a tongue of tumour extending centrally to the porta hepatis
was not fully ablated and was apparent on postoperative imaging.
The patient was treated with transarterial chemoembolization. On
surveillance imaging, five patients with HCC were found not to
have recurrence at an average follow-up of 6.8 months (range:
3–12 months). Two patients with HCC and all of the patients with
secondary liver metastases suffered from regional recurrences
during surveillance imaging.
Discussion
Hepatic tumour ablation has become a mainstay in the treatment
of both primary and metastatic lesions.13–15 Local recurrence
attributable to incomplete thermal ablation remains a major
concern despite advances in imaging, ablation system design and
surgeon training. Reported incidences of incomplete hepatic abla-
tions are typically under 5%16 and some series have reported rates
as low as 2.8%,17 although others report considerably higher fre-
Figure 2 Stereoscopic display for visualizing real-time three-
dimensional images
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Figure 3 Stereoscopic three-dimensional display showing (a, b) images of the ultrasound transducer and the real-time ultrasound images,
and (c) the same probe as it is positioned in 3-D space relative to the microwave antenna, shown here penetrating the tissue. (d) A red ‘cage’
graphic is superimposed to illustrate the size of the ablation cavity at the current power settings
Table 1 Demographic and clinical data for the 13 patients enrolled in this study
Patient Age,
years
Sex Diagnosis Lesions, n Operative time,
min
Length of stay,
days
Morbidities
1 43 F Colorectal cancer 5 177 5 –
2 85 M HCC 1 62 2 –
3 63 F Small bowel synovial sarcoma 2 83 2 –
4 49 M HCC 2 108 3 Mild hypoxia
5 56 M HCC 2 118 4 –
6 52 M Carcinoid 4 46 2 –
7 46 M HCC 1 52 2 –
8 62 F HCC 5 134 6 Ileus, delirium, hypertension
9 57 M HCC 1 64 2 –
10 70 M Carcinoid 5 96 3 –
11 63 M HCC 1 77 1 –
12 60 F Lung 3 113 8 Hypoxia
13 66 M HCC 2 65 2 –
F, female; M, male; HCC, hepatocellular carcinoma.
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quencies.18 Several factors may contribute to the reported inci-
dence of incomplete ablations, including: the size of the series;
whether the study reports primary, secondary, or primary and
secondary tumours; whether the study was conducted in a single
or multiple centres; the inclusion and exclusion criteria for eli-
gibility; the type of ablation performed (radiofrequency ablation
or MWA), and the experience of the surgeon.13,16,19
Even for the experienced surgeon, US targeting remains the
most challenging aspect of a laparoscopic ablation. This is
because, using currently available equipment, the performance of
3-D tasks using 2-D images as reference points requires the
surgeon to mentally visualize the spatial relationships between the
US probe, the ablation device and the lesion, a task that becomes
even more difficult in laparoscopy.20,21 For both novice and experi-
enced operators, ablations performed in the plane of the US image
are more easily accomplished as the surgeon is able to see both the
lesion and the tract of the needle during placement on the US. In
reality, these optimal circumstances are not always possible and
the placement of the ablation antenna must be achieved out of
plane with the US. When this occurs, the lesion and needle do not
appear on screen together until the needle passes the plane of the
US. As a result, a full pass with the antenna is (usually) required
before an error in targeting can be appreciated. Data from the
present group using in vitro and ex vivo models report a first-time
success rate of approximately 60% in expert hands. This means
that to acquire a lesion out of plane for ablation (often) requires
multiple full passes to accurately target the lesion, which intro-
duces the risk for additional tissue trauma, a potential for tumour
seeding and increases the time spent in the operating room.
Several commercially available computer-assisted navigational
systems, developed specifically for liver and pancreas surgeons, are
currently available or in development. These systems include
those produced by InnerOptic Technology, Inc., Pathfinder Tech-
nology, Inc. (Nashville, TN, USA) and CAScination AG (Bern,
Switzerland). These systems have many similarities and differ-
ences. All three systems continuously track the positions of the
intraoperative US probe and the ablation needle and display these
to the surgeon. Currently, the Pathfinder and CASination systems
use optical tracking systems, which require reflectors to be
attached to the handles of the needle and US probe, and cannot
yet account for the flex of the US probe or needle shaft. The
InnerOptic system uses an electromagnetic sensor at the tip of the
needle and probe in order to account for the bending of the probe
and needle. The InnerOptic and Pathfinder systems can be used
laparoscopically, whereas the CASination system is currently
applicable only to open procedures. CASination and Pathfinder
require the user to process the preoperative CT images and to
identify the boundaries of the liver and blood vessels. The surgeon
must then register this preoperative plan to the patient’s liver
during the surgical procedure. The benefit of this is that the
surgeon can see the live real-time position of the needle relative to
the preoperative plan. The correspondence is not perfect because
the tissue deforms between the time of the preoperative CT and
the surgical procedure, and also during the surgical procedure
itself as the surgeon manipulates the liver. In comparison, the
InnerOptic system is simpler and faster to use (no preoperative
workflow, planning or registration is required), but it does not
show the locations of blood vessels or tumours beyond those
apparent in the liver US images. It is important to note that all
three systems are under constant and rapid development and the
comparison of the three systems is subject to change with time.
Previous reports from the present group on the use of 3-D
guidance for ablation in open surgery, and on the use of
laparoscopic devices in simulation, showed significant increases in
first-attempt success rates. For example, using a laparoscopic
system in a simulated in vitro setting demonstrated a 100% first-
time success rate in the hands of experts and significantly
increased the accuracy of novice and intermediate users.11 The
data presented herein support these findings in a prospective
human trial in which a first-attempt success rate of 93% was
achieved (n = 45 ablations). However, this study involved relatively
few patients (n = 13) and all of the ablations were performed by
surgeons who fall into the ‘expert’ category based on their prior
experience and history of using MWA to treat hepatic tumours. To
further demonstrate the potential of this technology it would thus
be important to increase both the cohort size and the number of
Figure 4 (a) Computed tomography (CT) shows a solitary hepatocellular carcinoma centrally located in the liver. (b) The first post-ablation
CT demonstrates the complete ablation of the tumour. (c) This patient remains disease-free on further follow-up imaging at 14 months
post-ablation
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different surgeons using the technology. In such an investigation,
it would be important to collect longterm outcomes and
follow-up in order to factor in surgeon experience, the type of
cases in which the technique was employed, and the underlying
aggressive nature of HCC and secondary metastatic diseases of the
liver.13–15 Unfortunately, this study was limited by an inability to
acquire additional MWA antennae as these were custom-built
prototypes (with the position sensor at the tip) and production
has been halted.
In conclusion, the InnerOptic AIM™ 3-D guidance system
removed the limitations imposed by line-of-sight issues that arose
with an earlier IR 3-D guidance system. The InnerOptic AIM™
3-D guidance system is seamlessly integrated for use in laparos-
copy and was found to significantly improve both accuracy and
first-pass success rates.
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